

David R. Dodds, Ph.D.

David Dodds has over 30 years experience leading interdisciplinary process development groups combining biological and chemical technologies to create new industrial processes. His experience spans academic, venture, legal, and industrial cultures, from creating technical strategy, to plant operations facing decisions in process scale-up, to directing hands-at-the-bench scientists solving problems in basic science. He has extensive experience working under GMP for API production via fully synthetic processes, semi-synthetic, and natural product fermentation processes, and provides services covering the CMC sections of IND & NDA filings, technical due diligence for parties considering new technologies, and as an expert witness for patent litigation.

David's last corporate position was Director of Fermentation and Biocatalysis Development at Bristol-Myers Squibb. Among other responsibilities, he reviewed all third-party technology for the production of paclitaxel that was presented to BMS, and managed the scale-up of the fermentation for epothilone, the natural product used to produce the anticancer drug IXEMPRA® (Ixabepilone).

Prior to his invitation to BMS, David established and led the Biotransformations Group within Chemical Development at the Schering-Plough Research Institute (now Merck). His group successfully introduced biocatalysis in over a dozen projects, including the anti-cholesterol drug Zetia® and the anti-fungal Posaconazole®.

Most recently, David served as interim CTO for Azitra, Inc., a microbiome start-up. David is co-founder of SriyaDXI, an IT start-up that uses machine learning to determine user experience during digital transactions. He was previously CTO for Pronghorn Renewables (now Sriya Green Enterprises), a bio-based chemical start-up targeting products from C5 sugars using process technologies from the petrochemical industry. He is a principal at BioChemInsights, which is using electrochemistry to improve the carbon efficiency and avoid CO₂ generation in biological processes for the production of renewable fuels and bio-based chemicals. He consults with RondaxePharma, and is a member of the Renewable Chemicals team at Lee Enterprises Consulting.

David pursued post-doctoral work in molecular biology with Marvin Caruthers at the University of Colorado (1984-1986), Boulder. He obtained his Ph.D. in synthetic organic chemistry under Bryan Jones at the University of Toronto in 1984.

